WebJan 1, 2016 · CGF166 was designed by GenVec and utilizes our proprietary GV11 gene delivery system, featuring an E1-, E3-, E4-deleted human adenovector serotype 5 (Ad5) backbone. CGF166 also features a cell-specific promoter that limits the expression of the atonal gene to the supporting cells of the inner ear. WebAug 7, 2024 · The Novartis gene therapy, called CGF166, uses a virus to reintroduce the gene into the cochlea, the part of the inner ear that receives sound. This approach is meant flip the switch to the “on”...
Safety, Tolerability and Efficacy for CGF166 in Patients With ...
CGF166 is recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA. The purpose of the study is to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through intra-labyrinthine infusion to improve hearing and vestibular function. This clinical trial is closed for enrollment. WebCGF166 is a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1). The goal of the study was to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through IL … peterborough brew pubs
Now Hear This: Akouos Secures $50M for Hearing Loss Gene ... - Xconomy
WebCGF 166 Alternative Names: CGF166; Hearing loss gene therapy Latest Information Update: 14 Jan 2024 Price : $50 * Buy Profile Adis is an information provider. We do not … WebInformation About This Flight On Other Days. For flights prior to the results below, please use our Historical Flight Status feature. 30-Mar. 31-Mar. 01-Apr. 02-Apr. 03-Apr. WebMay 20, 2024 · CGF166 is a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1). Detailed Description: The study will evaluate the safety, tolerability, and potential efficacy of CGF166 and the associated delivery procedures in patients with severe-to-profound unilateral or bilateral hearing loss. peterborough breaking news